Search PubMed⌕ Search

Biomedical subjects

G B Ryan

Publications and source records attributed to G B Ryan.

128 records · Page 8Linked to original sources

Podocyte architecture in puromycin aminonucleoside-treated rats administered tungsten or allopurinol.

The role of xanthine oxidase as a source of reactive oxygen species in puromycin aminonucleoside nephrosis was examined. The effects of allopurinol (a xanthine oxidase inhibitor as well as a reactive oxygen species scavenging enzyme) and tungsten (a specific xanthine oxidase inhibitor) on glomerular epithelial cell ultrastructure, renal xanthine oxidase and xanthine dehydrogenase activity, and urinary protein excretion were examined in puromycin aminonucleoside-treated rats. Co-administration of allopurinol to such rats reduced proteinuria by approximately 70% over the 10 days studied, and reduced the degree of glomerular epithelial cell foot process effacement at both 5 and 10 days, compared to rats that received puromycin aminonucleoside alone. Unexpectedly, co-administration of allopurinol to puromycin aminonucleoside-treated rats did not reduce xanthine oxidase activity; however, the combined activity of xanthine oxidase and xanthine dehydrogenase in such animals was reduced on day 5. Co-administration of tungsten to puromycin aminonucleoside-treated rats did not reduce proteinuria or alter the number of filtration slits. Rats co-administered tungsten and puromycin aminonucleoside had significantly reduced renal xanthine oxidase and combined xanthine oxidase and xanthine dehydrogenase activities on days 5 and 10, compared to rats treated with puromycin aminonucleoside alone. These results provide evidence that the protection provided by allopurinol in puromycin aminonucleoside-treated rats is due to the antioxidant properties of allopurinol, rather than to its activities as a xanthine oxidase inhibitor.

Allopurinol↗

Glomerular number and size following chronic angiotensin II blockade in the postnatal rat.

Chronic angiotensin-converting enzyme (ACE) inhibition with enalapril or angiotensin II (Ang II) receptor antagonism with either losartan (specific for Ang II type-1 receptor, AT1) or PD 123319 (specific for the Ang II type-2 receptor, AT2) were effected between postnatal days 3 and 21 in the rat. Following quantitative analysis of the kidneys using recently developed unbiased stereological techniques we found that none of the treatments resulted in changes in glomerular number or size. This implies that inhibition of Ang II activity had no effect on postnatal nephron induction or glomerular development. However, following both chronic ACE inhibition and AT1 antagonism, abnormalities of tubules and their associated vessels were evident throughout the kidney and were accompanied by an increased proportion of interstitium. The structural abnormalities were most prominent in the outer medulla and were consistent with interruption of descent of the loops of Henle and vasa rectae. In contrast, no renal morphological abnormalities were observed following chronic AT2 antagonism.

Abnormalities, Drug-Induced↗